ANDA 209251, held by Rising. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 209251 (Hydralazine Hydrochloride), held by Rising, was first approved by FDA on Jul 9, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 9, 2018 | Original application | Approved | None posted |
| Hydralazine Hydrochloride10MG · tablet;oral | Hydralazine Hydrochloride | Discontinued |
| Hydralazine Hydrochloride25MG · tablet;oral | Hydralazine Hydrochloride | Discontinued |
| Hydralazine Hydrochloride50MG · tablet;oral | Hydralazine Hydrochloride | Discontinued |
| Hydralazine Hydrochloride100MG · tablet;oral | Hydralazine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters